Cardiometabolic Diseases Market Size, Growth, Trends and Forecast 2035

Cardiometabolic Diseases Market Trends for 2026

The global cardiometabolic diseases market size is predicted to increase from USD 292.04 billion in 2026 to approximately USD 1987.69 billion by 2035, expanding at a CAGR of 23.75% from 2026 to 2035.

The increasing incidence of cardiometabolic disease globally is increasing the demand for effective treatment and accurate diagnostic solutions, where the use of AI is driving their innovations. The robust healthcare, growing health awareness, and government initiatives are also increasing their use across various regions, where the companies are also investing and launching new products, promoting the market growth.

Key Takeaways

• The cardiometabolic diseases market will likely exceed USD 292.04 billion by 2026.
• Valuation is projected to hit USD 1987.69 billion by 2035.
• Estimated to grow at a CAGR of 23.75% starting from 2026 to 2035.
• North America held the major revenue share of approximately 37% in the global cardiometabolic diseases market in 2025.
• Asia Pacific is expected to grow at the fastest CAGR of approximately 15% during the forecast period.
• By disease type, the hypertension segment held an approximate 50% share in the market in 2025.
• By disease type, the obesity segment is expected to grow at the fastest CAGR of approximately 13% during the forecast period.
• By therapeutic class type, the antihypertensives segment held an approximate 47% share in the market in 2025.
• By therapeutic class type, the antidiabetics segment is expected to grow at the fastest CAGR of approximately 17% during the forecast period.
• By treatment modality type, the pharmaceuticals segment held an approximate 60% share in the market in 2025.
• By treatment modality type, the digital health/telemedicine segment is expected to grow at the fastest CAGR of approximately 19% during the forecast period.
• By end user, the hospitals & cardiology centers segment held an approximate 48% share in the market in 2025.
• By end user, the home care & remote monitoring segment is expected to grow at the fastest CAGR of approximately 20% during the forecast period.

What are the Cardiometabolic Diseases?

Cardiometabolic diseases are interconnected conditions affecting cardiovascular and metabolic health, including hypertension, coronary artery disease, heart failure, type 2 diabetes, obesity, dyslipidemia, and metabolic syndrome. The cardiometabolic diseases comprise the epidemiology, diagnosis, treatment, monitoring, and management of conditions that affect the heart and metabolic systems. Cardiometabolic diseases include cardiovascular diseases (e.g., coronary artery disease, heart failure, hypertension), metabolic disorders (e.g., type 2 diabetes, obesity, dyslipidemia), and overlapping syndromes like metabolic syndrome that increase risk of morbidity and mortality.

AI Technological Shifts in the Cardiometabolic Diseases Market

AI is being evaluated and deployed for risk prediction, medical-image analysis, clinical decision support, patient monitoring, and analysis of electronic health and laboratory data. Personalized treatment plans and drug development and optimization are also supported with the use of AI, where wearable devices and apps are also being developed with its use. It is also used in the design of clinical trials, which helps in reducing manual errors.

What are the Trends & Future Outlook of the Cardiometabolic Diseases Market?

Growing Adoption of Advanced Therapies

To deal with the growing incidence of cardiometabolic diseases, the healthcare sector is increasingly adopting various novel and personalized therapies along with other combination drugs.

Expansion of Pharmacotherapy

Hospitals and clinics are increasingly combining pharmacological treatment with lifestyle interventions and longitudinal disease monitoring to support cardiometabolic disease management.

Expansion of Digital Health and Remote Monitoring

The companies are developing various mobile apps, wearable devices, and telemedicine platforms for early disease detection and their continuous monitoring, which are backed by investments.

What are the Major Investments in the Cardiometabolic Diseases Market?

• In November 2025, an investment from Highcroft Capital was announced by VenstraMedical, which is a cardiovascular medical device company, where the capital will be used to enhance the development of next-generation percutaneous ventricular assist device (pVAD).
• In July 2025, Kardium raised USD 250 million to support the commercial launch of its Globe Pulsed Field System and expand manufacturing capabilities.
• In February 2025, a total of $925 million up-front cost will be provided by Novartis for the acquisition of Anthos Therapeutics, which will help to expand the prospects in cardiometabolic disease of Novartis.

Quick Facts Table

Segmental Insights

By Disease Insights

Why Did the Hypertension Segment Dominate in the Cardiometabolic Diseases Market in 2025?

The hypertension segment held the largest share of approximately 50% in the market in 2025, due to growth in stressful conditions. Moreover, their complications led to various heart diseases and diabetes. This, in turn, increased the demand for various accurate diagnostic and effective treatment options.

Obesity

The obesity segment is expected to show rapid growth with approximately a 13% CAGR during the predicted time, due to a growing sedentary lifestyle. At the same time, the growing processed food consumption and calorie intake are also increasing the obesity rates. The growing health awareness is also driving their early diagnosis.

By Therapeutic Class Insights

How Antihypertensives Segment Dominated the Cardiometabolic Diseases Market in 2025?

The antihypertensives segment led the market with approximately 47% share in 2025, due to growth in the hypertension rates. This increased the use of various hypertensive drugs, where their long-term use increased their repeated demand. Additionally, the presence of generic products also increased their affordability.

Antidiabetics

The antidiabetics segment is expected to show the highest growth with approximately 17% CAGR during the predicted time, due to increasing diabetes cases. Furthermore, the sedentary lifestyles, genetic factors, and dietary changes are also increasing their incidences, driving the demand for antidiabetics.

GLP-1 RAs & SGLT2 Inhibitors

In the antidiabetics segment, the GLP-1 & SGLT2 inhibitors subsegment is expected to show the fastest growth rate, due to their enhanced efficacy. Moreover, their proven weight management and cardiovascular risk reduction are also increasing their acceptance rates, which is driving their innovations.

By Treatment Modality Insights

Which Treatment Modality Type Segment Held the Dominating Share of the Cardiometabolic Diseases Market in 2025?

The pharmaceuticals segment held the largest share of approximately 60% in the market in 2025, due to growth in the R&D activities. Additionally, the growth in cardiometabolic diseases also increased the use of various treatments and diagnostic options, which promoted their adoption rates and advancements.

Digital Health/Telemedicine

The digital health/telemedicine segment is expected to show rapid growth with approximately 19% CAGR during the upcoming years, due to growing focus on remote monitoring. This, in turn, is encouraging the development of wearable and personalized care options, which are attracting patients.

By End User Insights

What Made Hospitals & Cardiology Centers the Dominant Segment in the Cardiometabolic Diseases Market in 2025?

The hospitals & cardiology centers segment led the market with approximately 48% share in 2025, due to growth in the patient volume. This increased the use of various diagnostics and treatment options. Moreover, their reimbursement policies and use of complex therapies also increased their acceptance rates.

Home Care & Remote Monitoring

The home care & remote monitoring segment is expected to show the highest growth with approximately 20% CAGR during the upcoming years, due to the early detection of disease complications. This increased their use for continuous disease monitoring, driving the demand for telemedicine and wearable devices.

Regional Distribution

• North America accounted for approximately 37% of global cardiometabolic diseases market revenue in 2025.
• The U.S. led the market by capturing the largest revenue share of the market in 2025.
• Asia Pacific is expected to be the fastest-growing region with approximately 15% CAGR in the studied years.
• India is anticipated to grow at a rapid CAGR during the forecast period.
• Europe is expected to grow at a notable CAGR in the cardiometabolic diseases market during the forecast period.
• The UK is anticipated to grow at a rapid CAGR during the forecast period.

Why Does North America Account for the Largest Regional Share?

North America dominated the cardiometabolic diseases market with approximately 37% share in 2025, due to the presence of an advanced healthcare infrastructure. At the same time, the growth in cardiometabolic diseases is also increasing the adoption of various treatments and diagnostic options, along with digital platforms, which contributed to the market growth.

The growing incidence of cardiovascular disease in the U.S. is increasing the demand for effective treatment and accurate diagnostic devices. This is driving the adoption of various advanced therapies and digital health platforms. Investment in healthcare technologies and reimbursement frameworks can influence adoption of advanced therapies and digital health services across the region.

Why is Rapid Urbanization Boosting the Asia Pacific?

Asia Pacific is expected to host the fastest-growing cardiometabolic diseases market with approximately 15% CAGR during the forecast period, due to rapid urbanization, which is leading to lifestyle changes and increasing the incidence of various cardiometabolic diseases. The expanding healthcare and growing health awareness are also increasing the use of various disease management options, enhancing the market growth.

The growing incidence of diabetes and hypertension in India is increasing the demand for treatment options. The expanding healthcare is driving their adoption, where the growing health awareness is increasing their early diagnosis. The growing government initiatives are also increasing accessibility to their treatment options.

What Factors Support Cardiometabolic Disease Treatment in Europe?

Europe is expected to grow significantly in the cardiometabolic diseases market during the forecast period, due to growing hypertension and diabetes cases. At the same time, the presence of advanced healthcare systems is increasing the use of various advanced therapies, supported by reimbursement policies, which is promoting the market growth.

The presence of advanced healthcare systems is increasing the accessibility to a wide range of treatment options for cardiometabolic disease to control its growing incidence. Pharmaceutical and medical-technology companies are developing specialized therapies, monitoring technologies, and digital health solutions, while public-health programs support chronic-disease management.

Cardiometabolic Diseases Market Value Chain Analysis

R&D

• The R&D of the cardiometabolic disease focuses on the development of next-generation oral GLP-1 agonists, gene-silencing therapies, multi-receptor peptides, and SGLT2 inhibitor combinations.
• Key players: Novo Nordisk, Novartis, Eli Lilly and Company.

Clinical Trials and Regulatory Approvals

• The major adverse cardiovascular events (MACE) reduction, glycaemic control, and weight loss percentage are evaluated in the clinical trials and regulatory approval of cardiometabolic disease treatment.
• Key players: Novo Nordisk, Eli Lilly and Company, AstraZeneca.

Patient Support and Services

• Comprehensive patient support, financial assistance, and personalized coaching programs are provided in the patient support and services of cardiometabolic disease.
• Key players: Novo Nordisk, Eli Lilly and Company.

Who are the Top Vendors in the Cardiometabolic Diseases Market and What are Their Offerings

SWOT Analysis

Strength

• The growing incidence of cardiometabolic diseases is increasing the repeated use of various treatments and diagnostic options.
• The presence of a wide range of therapeutic options is increasing their accessibility, which helps in their management and control.
• The growth in the government initiatives is supporting cardiometabolic disease management.
• The companies are developing various diagnostic tools and advanced therapies for early diagnosis and effective treatment of the diseases.

Weakness

• High treatment costs act as the major weakness in the cardiometabolic disease markets, limiting their acceptance rates.
• Side effects associated with certain medications limit their use, leading to a rise in safety concerns.

Opportunity

• Expanding healthcare is leading to the growth in the treatment options, which is enhancing their accessibility.
• The growing health awareness is promoting the early diagnosis of various cardiometabolic diseases.
• The growing shift towards personalized medicines is increasing the development of targeted treatment options.
• Growing government chronic disease management programs are increasing the demand for cardiometabolic disease treatment options.

Threats

• Complex manufacturing acts as a major threat as it requires advanced facilities, leading to growth in the overall development cost.
• Stringent safety, effectiveness, and quality regulatory standard slow down their innovations.

Recent Developments in the Cardiometabolic Diseases Market

• On 30 October 2025, Avance Clinical announced the launch of its Renal & Cardiometabolic Center of Excellence to support clinical development, patient recruitment and retention, and study execution.
• In June 2025, WIDAPLIK™, a treatment targeting hypertension in adults, was announced to have received the U.S. Food and Drug Administration (FDA) approval, as per George Medicines.

Segments Covered in the Report

By Disease Type

• Coronary Artery Disease (CAD)
• Heart Failure
• Hypertension
• Type 2 Diabetes Mellitus
• Obesity
• Dyslipidemia (High Cholesterol)
• Metabolic Syndrome
• Other Cardiometabolic Conditions

By Therapeutic Class

• Antihypertensives
• ACE Inhibitors
• ARBs
• Beta-Blockers
• Calcium Channel Blockers
• Antidiabetics
• Insulin & Analogues
• Oral Glucose-Lowering Agents
• GLP-1 RAs & SGLT2 Inhibitors
• Lipid-Lowering Agents (Statins, PCSK9 Inhibitors)
• Anti-Obesity Drugs
• Antiplatelets & Anticoagulants
• Combination Therapies
• Other Cardiometabolic Agents

By Treatment Modality

• Pharmaceuticals
• Biologics
• Medical Devices
• Cardiac Stents/Valves/Devices
• Glucose Monitors & Insulin Delivery Systems
• Obesity Management Devices
• Diagnostics & Screening
• Digital Health/Telemedicine
• Lifestyle Management & Preventive Programs

By End-User

• Hospitals & Cardiology Centers
• Outpatient Clinics & Primary Care
• Specialty Diabetes & Metabolic Clinics
• Diagnostic Laboratories
• Home Care & Remote Monitoring
• Ambulatory Surgical Centers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe
    • Austria
    • Russia & Belarus
    • Türkiye
    • Albania
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • Taiwan
  • India
  • Japan
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• MEA
  • GCC Countries
    • Saudi Arabia
    • United Arab Emirates (UAE)
    • Qatar
    • Kuwait
    • Oman
    • Bahrain
  • South Africa
  • Egypt
  • Rest of MEA